Symptoms of lupus nephritis introduction

添加图片说明

Lupus nephritis is histologically evident in most patients with systemic lupus erythematosus (SLE), even those without clinical manifestations of renal disease. Evaluating renal function in SLE patients is important because early detection and treatment of renal involvement can significantly improve renal outcome.

Clinically, SLE usually presents with fever, weight loss (100%), arthralgias, synovitis, arthritis (95%), pleuritis, pericarditis (80%), malar facial rash, photodermatosis, alopecia (75%), anaemia, leukopaenia, thrombocytopaenia, and thromboses (50%).

About half of cases of SLE demonstrate signs of lupus nephritis at one time or another. Renal-specific signs include proteinuria (100%), nephrotic syndrome (55%), granular casts (30%), red cell casts (10%), microhematuria (80%), macrohematuria (2%), reduced renal function (60%), RPGN (30%), ARF (2%), hypertension (35%), hyperkalemia (15%) and tubular abnormalities (70%).

A diagram of the pathological changes in a glomerulus visible via electron microscopy in SLE nephritis. Black: immune complex; dark purple: basement membrane; pink: endothelium; green: visceral epithelium; light purple: mesangial cells
In histology, stage I (minimal mesangial) disease has a normal appearance under light microscopy, but mesangial deposits are visible under electron microscopy. At this stage urinalysis is typically normal.

stage II disease (mesangial proliferative) is noted by mesangial hypercellularity and matrix expansion. Microscopic haematuria with or without proteinuria may be seen. Hypertension, nephrotic syndrome, and acute renal insufficiency are rare at this stage.

stage III disease (focal lupus nephritis) is indicated by sclerotic lesions involving less than 50% of the glomeruli, which can be segmental or global, and active or chronic, with endocapillary or extracapillary proliferative lesions. Under electron microscopy, subendothelial deposits are noted, and some mesangial changes may be present. Immunofluorescence reveals the so-called "Full House" stain, staining positively for IgG, IgA, IgM, C3, and C1q. Clinically, haematuria and proteinuria is present, with or without nephrotic syndrome, hypertension, and elevated serum creatinine.

Diffuse proliferative lupus nephritis; photo shows the classic "flea-bitten" appearance of the cortical surface in the diffuse proliferative glomerulonephritides
stage IV lupus nephritis (diffuse proliferative) is both the most severe, and the most common subtype. More than 50% of glomeruli are involved. Lesions can be segmental or global, and active or chronic, with endocapillary or extracapillary proliferative lesions. Under electron microscopy, subendothelial deposits are noted, and some mesangial changes may be present. Immunofluorescence reveals the so-called "Full House" stain, staining positively for IgG, IgA, IgM, C3, and C1q. Clinically, haematuria and proteinuria are present, frequently with nephrotic syndrome, hypertension, hypocomplementemia, elevated anti-dsDNA titres and elevated serum creatinine.

Glucocorticoids plus either cyclophosphamide intravenously or mycophenolate mofetil orally should be administered to patients with class III/IV disease; patients with class I/II nephritis do not require immunosuppressive therapy

A wire-loop lesion may be present in stage III and IV. This is a glomerular capillary loop with subendothelial immune complex deposition that is circumferential around the loop. Stage V is denoted by a uniformly thickened, eosinophilic basement membrane. Stage III and IV are differentiated only by the number of glomeruli involved (which is subject to inherent sample bias), but clinically the presentation and prognosis are both expected to be more severe in stage IV versus stage III.

A final stage is usually included by most practitioners, stage VI, or advanced sclerosing lupus nephritis. It is represented by Global sclerosis involving more than 90% of glomeruli, and represents healing of prior inflammatory injury. Active glomerulonephritis is usually not present. This stage is characterised by slowly progressive renal dysfunction, with relatively bland urine sediment. Response to immunotherapy is usually poor.

Want to learn more knowledge of lupus, please consult our website

How to prevent lupus erythematosus

Lupus kidney disease

Erythematosus (sle) is a multi-body systems involving multiple organs, clinical manifestations of complex, prolonged course of repeated autoimmune diseases. Systemic lupus erythematosus can be divided erythematosus (SLE) and discoid lupus erythematosus (DLE) two categories. Subacute cutaneous lupus erythematosus (SCLE), is a range of skin lesions of discoid lupus erythematosus and systemic lupus erythematosus between.

1 foster optimism, properly treat the disease and establish the confidence to overcome the disease, patterns of life, pay attention to work and rest, proper rest, to prevent infection.
2 to remove a variety of incentives, including a variety of possible internal use of drugs, chronic infection foci, etc., to avoid irritating topical medications and all external stimuli.
3 Avoid sunlight and ultraviolet radiation, especially in the event of need, to add sunlight painted anti-drugs such as quinine 3% ointment, ointment compound of titanium dioxide, 15% for ammonia benzoin limp ointment, others such as cold, X-ray, etc. too much can also cause increased exposure to the disease, can not be ignored.
4. hydralazine, procainamide, penicillamine, antibiotics and sulfa drugs to reasonable effect.
5 Patients should birth control, activities of the need to avoid pregnancy, renal impairment or if system damage who should strive to make early therapeutic abortion.

a variant of lupus erythematosus that resolves within days to months after withdrawal of the culprit drug in a patient with no underlying immune system dysfunction. DILE can arise months to years after exposure to drugs prescribed to treat various medical conditions (eg, antihypertensives, antibiotics, anticonvulsants). The most common drugs that cause DILE are hydralazine, procainamide, quinidine, isoniazid, diltiazem, and minocycline (see Etiology).[1]

Drug-induced subacute cutaneous lupus erythematosus (DISCLE) is a DILE variant with predominant skin involvement, temporally related to drug exposure, and resolving after drug discontinuation.[2]

Care must be taken to correctly diagnose the symptoms of DILE and differentiate it from systemic lupus erythematosus (SLE), and DILE should be recognized clinically and serologically for prompt intervention.

Although both SLE and DILE are autoimmune disorders and can have similar clinical and laboratory features (see Table 1 below), research suggests different mechanistic pathways (see Pathophysiology). Guidelines for diagnosis and management of SLE have been established.[3] Although the pathogenesis of DILE is not completely understood, a genetic predisposition may play a role, as has been shown with certain drugs metabolized by acetylation, such as procainamide or hydralazine.[4]
Drugs such as procainamide, chlorpromazine, and quinidine cause the production of antinuclear antibodies against the histone dimer H2A-H2B. Hydralazine forms antinuclear antibodies to H1 and the H3-H4 complex.[6] Drugs that cause DILE usually take months to years before the associated symptoms occur, whereas flares of SLE due to drugs may occur within hours to days.

Most patients with DILE have 1 or more clinical symptoms of SLE, such as arthralgias, lymphadenopathy, rash, and fever, and have had no prior history of autoimmune disease. However, certain manifestations typical in persons with SLE are not usually observed in persons with DILE (see Clinical).

No specific criteria establish the diagnosis of DILE, and excluding underlying autoimmune disease is not a simple process. DILE is typically diagnosed by a process of elimination to rule out SLE (see Differentials).

Symptoms of DILE usually clear within weeks of stopping the culprit drug. Generally, no other specific treatments are known. Low doses of systemic corticosteroids may be prescribed for short periods if the symptoms are severe

To learn more, please contact me:sjzhospitalrenal@hotmail.com